In-Depth Notes on Hallmarks of Cancer and Targeted Therapy

ILOs (Intended Learning Outcomes)

  • Understanding Hallmarks of Cancer
  • Knowledge of updated hallmarks and enabling characteristics.
  • Importance in developing targeted therapies.
  • Clinical Application
  • Application of hallmarks in clinical practice.
  • Need for Precision in Therapies
  • Understanding the necessity for more precise, molecularly targeted therapies.
  • Kinase Inhibitors
  • Examples of kinase inhibitors as common types of targeted therapy.

Hallmarks of Cancer Overview

Initial Six Hallmarks (Hanahan, Douglas et al.)
  • Sustaining proliferative signaling
  • Evading growth suppressors
  • Resisting cell death
  • Inducing angiogenesis
  • Activating invasion and metastasis
  • Enabling replicative immortality
Updated Hallmarks and Emerging Characteristics
  • Core Hallmarks (as per Cancer Discov. 2022):
  • Sustaining proliferative signaling
  • Evading growth suppressors
  • Resisting cell death
  • Inducing angiogenesis
  • Activating invasion and metastasis
  • Enabling replicative immortality
  • Avoiding immune destruction
  • Tumor-promoting inflammation
  • Genome instability & mutation
Enabling Characteristics
  • Non-mutational epigenetic reprogramming
  • Phenotypic plasticity
  • Senescent cells
  • Polymorphic microbiomes

Deregulating Cellular Energetics

  • Alterations in metabolism:
  • Increased ATP production via enhanced glycolysis and biosynthesis.
  • Modifications in redox balance and transport mechanisms.
  • Implications for treatment:
  • Understanding metabolic changes is crucial for targeting tumor growth.

Avoiding Immune Destruction

  • Mechanisms of Evasion:
  • Cancer cells develop various strategies to evade immune targeting, including modulation of immune checkpoints.
  • Therapeutic Targets:
  • Novel strategies in immunotherapy focus on unraveling these evading mechanisms.

Tumor-Promoting Inflammation

  • Inflammation and Cancer:
  • Recognized as a significant factor in cancer initiation, growth, and metastasis.
  • Chronic inflammation may lead to genetic alterations and foster tumor progression.

Genome Instability and Mutation

  • Cancer Characteristics:
  • Accumulation of DNA damage due to the inability to repair leads to increased genomic instability and mutations.
  • Consequences:
  • This instability contributes to the aggressiveness and adaptability of cancer cells.

Kinase Inhibitors in Targeted Therapy

  • Types of Kinases:
  • Receptor tyrosine kinases (RTKs), serine/threonine kinases, and others are critical for cell signaling in cancer.
  • Examples of Therapies:
  • Numerous agents such as Alpelisib, Erlotinib, and Vemurafenib target specific kinases.
  • Mechanism of Action:
  • Kinase inhibitors work by blocking overactive pathways leading to uncontrolled cell growth.

Clinical Examples

  • Erlotinib in NSCLC:
  • Targets EGFR mutations leading to reduced tumor growth.
  • Vemurafenib:
  • Specifically targets the BRAF V600E mutation, blocking the aberrant signaling pathway.
  • Herceptin for Breast Cancer:
  • A monoclonal antibody targeting HER2 positive cancers to inhibit receptor signaling.

Summary on Targeted Therapy

  • Mechanisms of Targeting:
  • Targeting specific hallmarks through tailored therapies to minimize side effects and improve outcomes.
  • Importance of Biomarker Testing:
  • Essential for identifying suitable candidates for targeted therapies based on specific mutations or expressions.